HOME >> BIOLOGY >> NEWS
Ability to absorb calcium may slow rate of bone loss, find University of Pittsburgh researchers

Age-related declines in the amount of calcium absorbed by the body contribute to bone loss among older men, especially after the age of 80, according to Randi L. Wolf, Ph.D., research associate at the University of Pittsburgh Graduate School of Public Health, who presented these new findings from a long-term study Sunday, Oct. 3, at the national meeting of the American Society for Bone and Mineral Research (ASBMR).

"We found that as the men aged, the amount of calcium absorbed by their bodies dropped, putting them at increased risk of osteoporosis," said Dr. Wolf, principal investigator on the study. "This means that men should probably increase their consumption of calcium as they age to keep up with those losses and avoid the debilitating effects of osteoporosis."

The study evaluated 234 men ages 58-91 participating in the federally funded Study of Osteoporotic Risk in Men. Their bone mineral density was measured at baseline and again after 6.8 years. Low bone mineral density indicates the bone-weakening condition known as osteoporosis. At the follow-up, researchers also assessed participants' calcium absorption (a measure of how well the body absorbs calcium from the gut), body mass, dietary and supplemental calcium intake and a variety of lifestyle factors, along with blood levels of the hormones vitamin D, parathyroid, estradiol and testosterone.

Researchers found that calcium absorption decreased with age, dropping even more dramatically after the age of 80, and that higher levels of fractional calcium absorption were associated with slower rates of hip bone loss in aging men.

According to Dr. Wolf, "It appears that the hormonal form of vitamin D, which is the main regulator of intestinal calcium absorption, may have an important role. We are conducting more research to better understand the reasons for why calcium absorption declines with age in men."

At the ASBMR meeting, Dr. Wolf received a Young Investigator Award for her wor
'"/>

Contact: Kathryn Duda
dudak@msx.upmc.edu
412-624-2607
University of Pittsburgh Medical Center
4-Oct-1999


Page: 1 2

Related biology news :

1. Ability to smell food regulated by enzymes interaction with RNA interference pathway
2. UCSF Lab Makes Observation That Could Explain Ability Of Modified Cold Virus To Kill Cancer Cells
3. A Real Smart Asp: Snakes Show Surprising Ability To Learn
4. UCSF/Gladstone Finding May Explain HIVS Ability To Infect Cells Lacking The Key Target Of HIV: The CD4 Receptor
5. Researchers Identify Molecular Site That Is Key To HIVs Ability To Infect Cells Of Brain, Colon
6. Vions TAPET Organisms Demonstrate Reduced Virulence, Increased Safety While Retaining Ability To Specifically Target Tumors
7. Cell Pathways Reports Extension Study Results Showing Ability Of FGN-1 To Prevent Formation Of Precancerous Colon Polyps
8. Uterine Environment Boosts Learning Ability In Mouse Offspring
9. UPCI Researchers Find Drug Improves Cancer-Fighting Ability Of Vitamin D
10. Human-Like Ability, Categorical Perception, Found In Insects
11. Ocean plant life slows down and absorbs less carbon

Post Your Comments:
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
(Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
(Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, ... distribution agreement with VWR to distribute TECTA™ B16, ... than 160 years of experience, VWR, a leading ... and production facilities, has cultivated a value proposition ... to enable science. Endetec’s TECTA™ B16, combines ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
Cached News: